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Diagnosis and treatment of depression following
routine screening in patients with coronary heart
disease or diabetes: a database cohort study
C. Burton*, C. Simpson and N. Anderson
Centre for Population Health Sciences, University of Edinburgh, UK
Background. Depression is common in chronic illness and screening for depression has been widely recommended.
There have been no large studies of screening for depression in routine care for patients with chronic illness.
Method. We performed a retrospective cohort study to examine the timing of new depression diagnosis or treatment
in relation to annual screening for depression in patients with coronary heart disease (CHD) or diabetes. We
examined a database derived from 1.3 million patients registered with general practices in Scotland for the year
commencing 1 April 2007. Eligible patients had either CHD or diabetes, were screened for depression during the year
and either received a new diagnosis of depression or commenced a new course of antidepressant (excluding those
commonly used to treat diabetic neuropathy). Analysis was by the self-controlled case-series method with the
outcome measure being the relative incidence (RI) in the period 1–28 days after screening compared to other times.
Results. A total of 67358 patients were screened for depression and 2269 received a new diagnosis or commenced
treatment. For the period after screening, the RI was 3.03 [95% conﬁdence interval (CI) 2.44–3.78] for diagnosis and
1.78 (95% CI 1.54–2.05) for treatment. The number needed to screen was 976 (95% CI 886–1104) for a new diagnosis
and 687 (95% CI 586–853) for new antidepressant treatment.
Conclusions. Systematic screening for depression in patients with chronic disease in primary care results in a
signiﬁcant but small increase in new diagnosis and treatment in the following 4 weeks.
Received 29 February 2012 ; Revised 3 June 2012 ; Accepted 7 June 2012 ; First published online 18 July 2012
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Introduction
Patients with chronic illnesses, including coronary
heart disease (CHD) and diabetes, have an increased
prevalence of depression, with rates estimated to be
15–20% (Ali et al. 2006 ; Whooley et al. 2008), and this
is associated with impaired quality of life (Moussavi
et al. 2007). Much of this depression seems to be
unrecognized or untreated (Pouwer et al. 2006). The
ﬁnding that structured depression treatment in
patients with chronic illness leads to beneﬁt in terms
of mood and well-being (Katon et al. 2004 ; Davidson
et al. 2010) has led to recommendations to screen
for depression (Lichtman et al. 2008 ; NICE, 2009b ;
IDF, 2011).
Within the UK, the Quality and Outcomes
Framework (QOF), a nationally implemented pay-for-
performance scheme (Doran et al. 2006), introduced
routine annual screening for depression for all patients
with CHD or diabetes in primary care in April 2006.
This has been widely adopted by primary care prac-
tices, with 90% of eligible patients with CHD or
diabetes in Scotland screened during the 2007–2008
contract year (ISD Scotland, 2011). This screening
comprises a clinician [most commonly a practice nurse
but sometimes the general practitioner (GP)] asking
the patient two validated questions (Whooley et al.
1997), with additional questions or follow-up if either
of the answers is positive. The two questions used are :
‘During the last month, have you often been bothered
by feeling down, depressed or hopeless? ’ and ‘During
the last month, have you often been bothered by
having little interest or pleasure in doing things?’
Screening is typically carried out as part of a chronic
illness review consultation but may occur opportu-
nistically at other times, including if a patient with
CHD or diabetes presents with depression. Estimates
of the diagnostic accuracy of two-item depression
screeners suggest a sensitivity of 80–90% and a speci-
ﬁcity of 60–80% (Whooley et al. 1997 ; Thombs et al.
2008b ; Arroll et al. 2010).
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Despite this enthusiasm for screening patients with
chronic illnesses for depression, there are questions
about its usefulness (Thombs et al. 2008a ; Ziegelstein
et al. 2009 ; Pouwer, 2009). There have been no
studies in which screening for depression in patients
with CHD or diabetes by their usual professional
(as opposed to by researchers) has been linked to
depression outcomes. Qualitative studies have ident-
iﬁed practical diﬃculties in detecting and dealing
with depression in consultations for physical health
problems (Coventry et al. 2011) and evidence from
more general primary care studies suggests that
screening for depression does not improve outcomes
(Gilbody et al. 2005) and is unlikely to be eﬀective
without additional interventions (Thombs et al. 2008a ;
O’Connor et al. 2009 ; Pouwer, 2009 ; Ziegelstein et al.
2009).
We hypothesized that if screening for depression
in patients with diabetes and CHD in routine pri-
mary care is eﬀective, it should lead to more new
cases being diagnosed and treated in the weeks fol-
lowing screening compared to other time periods.
As screening, diagnosis and treatment of depression
are routinely recorded in primary care, we sought to
measure the impact of screening on the diagnosis
and treatment of depression within a large primary
care database using the self-controlled case-series
method. Speciﬁcally, we aimed to test the impact
of screening by comparing the incidence of new
depression diagnosis and antidepressant treatment
between the time period following screening and
other times.
Method
Data sources
We examined data from the Primary Care Clinical
Informatics Unit Research (PCCIUR) database held
by the University of Aberdeen. The PCCIUR data-
base comprises anonymized extracts from the
General Practice Administration System for Scotland
(GPASS) clinical information system. This was the
most widely used general practice clinical database
in Scotland at the time of the study and was used
for issuing almost all prescriptions and recording
clinical codes and demographic data. For the obser-
vation period of 12 months commencing 1 April
2007, it contained data from 1280840 patients regis-
tered with 237 general practices containing 1245
GPs. The patients registered with these practices
have been found to be representative of the
Scottish population (5.1 million) (Elder et al. 2007).
The study was approved by the PCCIUR steering
committee. As an anonymized database was used
for this research, ethical committee approval was not
required.
Subjects and exposures
The sample in our study comprised all patients in the
PCCIUR database during the observation period who
met three criteria : (1) a recorded diagnosis of CHD
and/or diabetes (Read codes in the online Appendix)
before the study start date ; (2) a record of screening
for depression either once or twice during the study
period; (3) either a new diagnosis of depression
or initiation of an eligible antidepressant during
the observation period. We deemed screening to have
occurred if the records included the relevant Read
code. As this code was used to measure QOF per-
formance and hence inﬂuenced practice remuneration,
practice staﬀ were encouraged to record it whenever
screening was carried out. Practices were not con-
tractually required to code all new diagnoses of de-
pression ; if the diagnosis was entered in the text of
the clinical record but not explicitly coded, we could
not identify it. When GPs did code a new diagnosis
of depression, they were contractually required to
carry out, and record, a formal assessment of severity
(Moore et al. 2009 ; Burton et al. 2012). For this reason
we used either a coded diagnosis of a depressive dis-
order or initiation of antidepressant treatment. Eligible
diagnostic codes included pure depression and mixed
anxiety and depression and are listed in the online
Appendix. Both were deemed to be new if they were
recorded during the observation period but not in the
12 months preceding this. As GPs sometimes recorded
codes for depressive symptoms (such as ‘ low mood’),
we carried out a sensitivity analysis that included
these. Eligible antidepressant drugs included those
commonly used for depression, including selective
serotonin reuptake inhibitors (SSRIs) and most sero-
tonin–norepinephrine reuptake inhibitors (SNRIs), but
excluded antidepressant drugs that are commonly
prescribed for diabetic neuropathy and other painful
conditions (amitriptyline and other tricyclic anti-
depressants and duloxetine) as these are no longer
recommended for initial treatment of new depression
(NICE, 2009a).
Exclusion criteria
For the primary analysis, we excluded patients who
were diagnosed or began treatment on the same day
as screening because we recognized that when a GP
diagnosed or initiated treatment for a patient present-
ing with depression, they might record the patient
as having been screened. We took this decision based
on contextual knowledge of UK primary care : most
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depression screening for patients with CHD and dia-
betes is carried out by nurses working semi-autono-
mously, whereas diagnosis and treatment (whether
following screening or of patients presenting with
symptoms of depression) is carried out separately
by GPs. This contextual detail is expanded in Table 1.
To test the eﬀect of this assumption on our results, we
conducted a sensitivity analysis that included patients
who were screened and diagnosed on the same day.
Statistical methods
We measured the relationship between screening and
either a new depression diagnosis or antidepressant
prescribing using the self-controlled case-series
method. This method, which has been described
extensively (Whitaker et al. 2006), investigates the
association between a time-varying exposure (i.e.
screening) and an event (i.e. depression diagnosis
or treatment). By including only cases with both
an exposure and an event, the temporal relationship
between exposure and events can be examined
for each individual, thereby controlling for inter-
individual diﬀerences.
We reasoned that a new diagnosis or treatment
following screening should occur within the exposure
period deﬁned as 1–28 days after the screening day.
Therefore, we allocated all events (depression diag-
nosis or prescribing) occurring during the observation
period to one of three categories : occurring before,
during or after the exposure period following de-
pression screening. We then determined the relative
incidence (RI) of being diagnosed or treated for de-
pression in this period compared to at other times.
To illustrate the relative impact of screening, we also
plotted bar charts in which each bar represented a
28-day block, with the central bar representing the
exposure period of 28 days after screening and the
remainder extending up to 20 weeks before and after
this (data from the screening day were omitted). We
checked the validity of using 28-day exposure period
and blocks by examining weekly trends to ensure we
did not lose data with this approach. For each patient
we allocated their event (diagnosis or new treatment)
to one 4-week block and calculated the event rate for
each block as the number of events divided by the
number of patients in the block.
We estimated the absolute impact of screening
by determining the increased number of patients di-
agnosed or treated for depression in the 28 days after
screening. This was calculated by dividing the ob-
served number of diagnoses and treatments during
the 4 weeks after screening by the RI and then sub-
tracting this from the observed number of diagnoses
to give the additional number of patients diagnosed or
treated [with 95% conﬁdence intervals (CIs)]. From
this, we were able to calculate the number needed
to screen to obtain one new diagnosis or treatment
by dividing the total screened population by the ad-
ditional number of patients diagnosed or treated.
We addressed the problem of patients with multiple
screening events during the study period but only one
new diagnosis or treatment in several ways. Where
patients were screened twice in the year, we calculated
the relative incidence based on the ﬁrst recorded epi-
sode of screening. Patients who were screened three
or more times were excluded because of the diﬃculty
of choosing between screenings. In addition, we car-
ried out two sensitivity analyses : ﬁrst, we analysed
only those patients with a single screening event and,
second, we analysed the data using the screening
event closest in time to the diagnosis of depression or
Table 1. Contextual information used in interpreting diagnosis or treatment on the same day as screening
(a) Screening leading to diagnosis
Within UK primary care most routine diabetes care is carried out by primary care nurses working within general practices
but autonomously from the general practitioners (GPs), who generally have fully booked clinic lists running in parallel with
their nurses. This means that all but the most urgent cases for referral from nurse to GP are asked to make another
appointment to see the GP, which will usually be on another day.
(b) Diagnosis leading to apparent ‘ screening ’
Under the Quality and Outcomes Framework (QOF) of the UK GP contract at the time of this study, if a GP made a diagnosis
of depression this is required to be supported by completion of a validated assessment tool, usually the nine-item Patient
Health Questionnaire (PHQ-9 ; Kroenke et al. 2001). If the GP completed the PHQ-9 then the computer system would
automatically code the patient as having been screened (as the PHQ-9 includes the two designated screening questions).
Even without coding a PHQ-9 score, a GP managing a patient presenting with depression who coincidentally had diabetes
or coronary heart disease (CHD) could also include, and record, the screening questions as part of that process.
(c) Exemption from screening
If a GP diagnosed or began treating a patient for depression but did not record them as screened at the time, they later
exempt them from the contractual requirement to screen because they were already receiving treatment.
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antidepressant treatment. For the secondary analysis
including patients with diagnosis or treatment on the
same day as screening, we used this date. All analyses
were conducted in R 2.14 (R Development Core Team,
2011) ; the self-controlled case-series analysis used
the script published by the originators of the method
(Whitaker et al. 2006).
Results
Patients and screening
At the start of the study period, 94 570 (7.4%) patients
had a diagnosis of CHD or diabetes and, of these,
67 358 (71.2%) were screened at least once for de-
pression during the study year. A total of 3707 (3.9%)
patients with diabetes or CHD were either diagnosed
with depression or began eligible antidepressant
treatment during the year, of whom 2269 (61.2%) were
screened for depression during the year. These
patients were screened on a total of 2838 occasions ;
1792 patients were screened once, 406 twice and 71
three times or more. Of those screened once or twice,
347 patients were recorded as screened on the same
day they received a diagnosis of depression (233
patients) or began treatment (221 patients). These were
excluded from the primary analysis. This left 1851
patients eligible for analysis, of whom 517 (27.9%)
patients received a diagnosis of depression. Of these,
428 also received new antidepressant treatment and 89
did not. There were 1334 (72.1%) patients who started
antidepressant treatment with no diagnostic code for
depression. These data are summarized in Fig. 1. The
demographic characteristics of included patients are
listed in Table 2.
Impact of screening
A new diagnosis of depression was recorded between
1 and 28 days after the ﬁrst screening during the study
Database total
population
1 280 840 
1 Screening recorded in the 12 months study period
2 New diagnosis of depression (relevant E.... or Eu... family read codes)
3 Eligible antidepressants: all commonly used antidepressants except amitriptyline 
  nortriptyline, imipramine and duloxetine.
4 Includes 1438 patients diagnosed or treated for depression but who were not screened:
  486 screened in the 3 months before the study, 182 exempted from screening, 169 coded 
  for depression assessment but not screening and 601 patients with no apparent reason.
Depression, &
antidepressant3
428
 
Depression2, no
antidepressant3
89 
 
Antidepressant3,
no diagnosis
1 334
Diabetes and/or CHD
94 570 
Screened 3 or more times
71 
‘Screened’ on same dayas
diagnosis or treatment
347 
No new diagnosis or
treatment for depression
65 089   
Screened1 for depression
67 358 
Not screened1  for depression4
27 112  
 
New diagnosis or treatment
for depression
2 269  
Fig. 1. Flow chart of entry into the study from the database.
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period in 103 (13.7%) patients who received a diag-
nosis within the study period (including on the same
day as screening). Diagnosis was recorded before
screening in 182 (24.3%) and more than 28 days after
screening in 232 (30.9%). Antidepressant treatment
was started between 1 and 28 days after the ﬁrst
screening in 225 (11.3%) patients receiving an anti-
depressant, before screening in 848 (42.8%) and more
than 28 days after in 689 (34.7%). Figure 2 shows
the relationship between ﬁrst screening and diagnosis
or starting treatment, excluding those patients re-
corded as screened and diagnosed or treated on the
same day.
The RI for diagnosis in the 4 weeks after the ﬁrst
screening was 3.03 (95% CI 2.44–3.78) and for treat-
ment the RI was 1.78 (95% CI 1.54–2.05). The absolute
impact of screening and the corresponding results
from the sensitivity analysis and the secondary
analysis including patients with treatment or diag-
nosis on the same day as screening are shown in
Table 3. The estimated ﬁgure of 69 (95% CI 61–76)
additional diagnoses following screening accounted
for 8.2% of all new diagnoses of depression in patients
with CHD or diabetes in the year (including patients
who were not screened). The comparable value
for additional new treatment of 98 (95% CI 79–115)
patients accounted for 2.8% of all newly initiated
antidepressant treatments. Given the total population
of patients screened in the study period of 67358, these
ﬁgures equate to a number needed to screen for one
new depression diagnosis of 976 (95% CI 886–1104)
and for one new antidepressant treatment of 687 (95%
CI 586–853) based on the ﬁrst screening and excluding
patients diagnosed or treated on the same day as
screening.
The sensitivity analyses that included symptom
codes in addition to depression diagnoses added
79 patients but made no diﬀerence to the results. The
results of the analysis including patients diagnosed
or treated on the same day as screening are shown in
Table 3. When these patients were included in the
analysis, the number needed to screen reduced to 232
for diagnosis and 203 for treatment.
Discussion
Summary of main ﬁndings
This is the ﬁrst database study to examine the impact
of systematic screening for depression in patients
with chronic illness in a community setting. Although
a new diagnosis of depression and initiation of anti-
depressant treatment were signiﬁcantly more common
in the 28 days after screening for depression, the ab-
solute number of patients diagnosed with depression
or beginning treatment after screening was small.
Strengths and weaknesses of this study
The large database used for this study is representa-
tive of the socio-economically diverse Scottish popu-
lation (Elder et al. 2007). Records of CHD and diabetes
diagnoses and screening are likely to be accurate
because they are recorded as part of the QOF payment
for performance scheme and subject to audit. The
recording of a diagnosis of depression is subject to
bias, such as diﬀerent coding behaviours between
practices : publicly available data show wide variation
in coding rates between geographically similar prac-
tices within Scotland (ISD Scotland, 2011). Records
of antidepressant treatment are likely to be complete
because practices contributing to the database use
computerized prescribing and the vast majority of
antidepressant prescriptions in Scotland are issued in
primary care, even when patients receive out-patient
specialist care. Although some of the antidepressant
prescribing may have been for indications other than
depression, we excluded those antidepressants com-
monly prescribed for diabetic neuropathy and have no
reason to suspect that screening for depression should
aﬀect any other indication for antidepressant treat-
ment. Conversely, we may have missed some patients
Table 2. Characteristics of patients screened and either diagnosed
with depression or starting antidepressant
Patients
n %
Age (years)
<35 40 2
36–65 852 46
>65 959 52
Sex
Male 804 43
Female 1047 57
Deprivation quintile
1 (Least) 196 11
2 279 15
3 471 25
4 475 26
5 (Most) 430 23
Medical diagnosis
CHD 1237 67
Diabetes 897 48
Both 293 16
Total 1851
CHD, Coronary heart disease.
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who were prescribed ineligible antidepressants for
depression ; however, given that these agents are
not recommended as ﬁrst-line drugs (NICE, 2009a),
this is unlikely to be important. We may also have
missed patients who were diagnosed (but not coded)
and referred for psychological treatment ; however,
drug treatment is prescribed for approximately
90% of patients managed with depression in UK
primary care and a similar proportion (83%) was seen
in our coded patients so it is unlikely that missing
patients would substantially alter our ﬁndings. Our
decision to use either antidepressant prescribing or
a diagnosis of depression rather than diagnosis
alone has been used previously (Burton et al. 2012),
and although it diﬀers from an English study using
a diﬀerent database (Moore et al. 2009), it reﬂects the
fact that the PCCIUR database does not require parti-
cipating practices to ensure all diagnoses are coded
and is thus more representative of routine general
practice.
We excluded patients from the primary analysis
who were recorded as screened on the same day that
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Fig. 2. The inﬂuence of screening on (a) diagnosis and (b) treatment. The event rate indicates the proportion of patients in each
time period who were diagnosed or started treatment. The time periods more than 20 weeks before and 24 weeks after screening
included smaller numbers of patients and have been omitted for clarity. Error bars indicate 95% conﬁdence intervals (CIs).
Patients diagnosed or starting treatment on the same day as screening were excluded. Data relate to the ﬁrst screening episode
in the study period.
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they were diagnosed with depression or began anti-
depressant treatment because contextual evidence
suggested that, in many cases, screening would be
recorded after a diagnosis or treatment in patients
presenting with depression, either by the GP or in
some cases by the GPASS computer system itself.
In other cases it was not recorded, possibly because
treatment was not for depression, possibly because
treatment was for another condition such as an anxiety
disorder, or simply because the practitioner did not
think to do it. This inﬂuenced our ﬁndings, and the
secondary analysis including these patients showed
a greater impact from screening. To examine the as-
sumption that it was more appropriate to exclude pa-
tients diagnosed or treated on the same day as
screening, we reviewed all instances of screening and
diagnosis on the same day. One hundred and seven
patients were recorded as having screening, diagnosis
and commencement of treatment all on the same day,
which we regarded as more in keeping with the pri-
mary reason for consultation being depression. A fur-
ther 126 patients only had screening and diagnosis
entered on the same date ; 80 of them had neither an-
tidepressant treatment nor codes that would indicate
assessment of a new episode of depression as stipu-
lated in the QOF. This pattern was more suggestive
of the GP entering a past diagnosis at the time of cur-
rent screening. Of the remaining 46 treated patients
with a new depression diagnosis on the same day
as ‘screening’, 22 had already received their new
antidepressant prescription before their ‘screening’
date, suggesting that some assessment of depression
had already been made before the screening was
coded. Although we show only a small direct eﬀect
of screening, we cannot exclude indirect eﬀects of
screening, such as raising awareness among patients,
nurses and GPs.
Generalizability of ﬁndings
The UK QOF is one of the ﬁrst provider schemes
to include systemic screening for depression in a
community population with chronic disease.
Compared to the results of trials of screening plus
coordinated care (Katon et al. 2004 ; Davidson et al.
2010), the number of new depression diagnoses and
courses of treatment in our study are disappointing.
However, a recent trial from tertiary diabetes centres
in The Netherlands (Pouwer et al. 2011) showed only a
non-signiﬁcant increase in use of mental health care
among patients after additional depression detection
and no measurable eﬀect on clinical outcomes. There
are substantial barriers to the recognition of de-
pression in the context of management of chronic
illness (Coventry et al. 2011) and to the initiation
of treatment when depression is not the patient’s
presenting complaint (Karasz et al. 2012). Previous
systematic reviews have reported that screening for
depression without additional care does not translate
into improved outcomes (Gilbody et al. 2005 ;
O’Connor et al. 2009) ; although we could not examine
outcomes of treatment, the very small increase in
patients commencing treatment after recognition
suggests that any diﬀerence in outcomes would have
been small.
Implications for policy, practice and research
Our ﬁndings suggest that screening for depression
leads to a statistically signiﬁcant but small number
of patients being diagnosed or receiving treatment
in the period following screening. By contrast, GP
practices diagnosed new depression and commenced
treatment independently of screening for almost 4%
of patients with CHD and depression during the
year ; this ﬁgure compares favourably with the 2.2%
Table 3. Results of the sensitivity analysis using the self-controlled case-series method
Analysis
Diagnosis of depression Starting antidepressant
RIa (95% CI)
Absolute excessb
n (95% CI) RIa (95% CI)
Absolute excessb
n (95% CI)
First screening onlyc 3.03 (2.44–3.78) 69 (61–76) 1.78 (1.54–2.05) 98 (79–115)
Patients only screened oncec 2.92 (2.26–3.79) 49 (42–55) 1.73 (1.47–2.03) 77 (58–92)
Nearest screening to eventc 2.91 (2.31–3.66) 63 (54–70) 1.88 (1.64–2.16) 116 (97–133)
Including cases diagnosed or
treated on same day as screening
10.59 (9.15–12.24) 308 (303–312) 3.52 (3.18–3.92) 322 (308–335)
RI, Relative incidence ; CI, conﬁdence interval.
a RI from self-controlled case-series analysis during the 4 weeks after screening of the speciﬁed event compared to other times.
b Absolute excess in cases in the 4 weeks after screening relative to the 4-week blocks either side of this.
c Excludes patients diagnosed or commencing treatment on the same day as screening.
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of the overall population who began antidepressant
treatment during the same year (Burton et al. 2012).
Together these results suggest, at least in health-care
systems in which primary care practitioners deal
with both physical and mental health problems, that
screening for depression leads to little additional rec-
ognition or treatment of depression in chronic illness
over standard care.
Given these ﬁndings we recommend careful con-
sideration before further extension of screening
for depression in patients with chronic illness. The
screening instruments themselves are commendably
brief and have reasonable predictive values, so it
may be that the way in which they are used could
be more eﬀective. Raising the issue of depression in
the context of a complex disease-monitoring consul-
tation may mitigate against its usefulness (Coventry
et al. 2011 ; Karasz et al. 2012), and it is possible that
administering the screening questions separately
from the consultation may lead to more cases being
detected. As current methods of brief screening in
routine consultations lead to few new cases being
treated, ﬁnancial incentives to promote screening may
be better used elsewhere, for instance in promoting
structured management for patients who are re-
cognized (Katon et al. 2004).
Conclusions
Routinely implemented screening for depression in
patients with CHD or diabetes leads to more cases
being diagnosed and treated in the 4 weeks after
screening than at other times. However, its absolute
impact is small and health-care systems should con-
sider the resource implications of current or additional
screening for depression in patients with chronic
disease.
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